Antibody-drug conjugate market projected to reach $453.9 billion by 2035

The antibody-drug conjugate (ADC) market is projected to grow from $14.23 billion in 2025 to $453.9 billion by 2035, representing a compound annual growth rate (CAGR) of 12.30% between 2026 and 2035.

ADCs are biopharmaceuticals that combine monoclonal antibodies with cytotoxic payloads to selectively deliver drugs to target cells, supporting the advancement of precision medicine. The industry is shifting from simple targeted therapies toward sophisticated next-generation platforms focusing on improved drug delivery, linker stability, and higher drug-to-antibody ratios (DAR).

Key developments include the 2025 US FDA approvals of Daiichi Sankyo’s DATROWAY for specific breast cancer and non-small cell lung cancer treatments. Additionally, the emergence of bispecific ADCs is a growing trend; for instance, NEOK Bio is developing dual-target therapies for ROR1/B7-H3 and EGFR/MUC1, with Phase 1 clinical trials expected to begin in mid-2026.